Search

everythinglearnresearchcommunity

for

Search:↓

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Oral baricitinib is effective and safe for treating alopecia areata.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

JAK inhibitors may help treat alopecia areata and promote hair regrowth.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Leflunomide successfully treated a rare skin condition in a liver transplant patient.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

A 589 nm laser increases IL-2 and IFN-y gene expression in human T-cells.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

Baricitinib is an effective treatment for severe alopecia areata.

A woman with asthma improved from a severe fungal infection after treatment change, and most HIV-positive women in a UK study had low immune cell counts but were responding well to treatment.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.